Krystal Biotech, Inc.

KRYS

$4.60B

Mid Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaPITTSBURGH275 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 1 past

⭐Phase 3Next

Placebo Phase 3 Results Expected

March 2026~KB80116

Primary completion for Placebo trial (NCT07016750) in Dystrophic Epidermolysis Bullosa

Source

⭐Phase 3

KB803 Phase 3 Results Expected

March 2026~KB80316

Primary completion for KB803 trial (NCT07016750) in Dystrophic Epidermolysis Bullosa

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Open Label Topical Beremagene Geperpavec (B-VEC)

Phase 3

Dystrophic Epidermolysis Bullosa

Topical beremagene geperpavec

Phase 3

Dystrophic Epidermolysis Bullosa

KB803

Phase 3

Dystrophic Epidermolysis Bullosa

KB801

Phase 2

Neurotrophic Keratitis

Opdualag

Phase 2

Cancer

KB707

Phase 2

Lung Cancer, Non-small Cell

KB304

Phase 2

Wrinkles in Decolletage

Drug Name	Phase	Indication	Designations
Open Label Topical Beremagene Geperpavec (B-VEC)	Phase 3	Dystrophic Epidermolysis Bullosa	-
Topical beremagene geperpavec	Phase 3	Dystrophic Epidermolysis Bullosa	-
KB803	Phase 3	Dystrophic Epidermolysis Bullosa	-
KB801	Phase 2	Neurotrophic Keratitis	-
Opdualag	Phase 2	Cancer	-
KB707	Phase 2	Lung Cancer, Non-small Cell	-
KB304	Phase 2	Wrinkles in Decolletage	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

KRYS News